{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:31:20Z","timestamp":1787020280363,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21dm0307102h0003"],"award-info":[{"award-number":["JP21dm0307102h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K10315"],"award-info":[{"award-number":["17K10315"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Maintaining remission after electroconvulsive therapy (ECT) is clinically relevant in patients with depression, and maintenance ECT has been introduced in patients who fail to maintain remission after ECT. However, the clinical characteristics and biological background of patients who receive maintenance ECT are poorly understood. Thus, this study aimed to examine the clinical background of patients who underwent maintenance ECT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with major depressive disorder who underwent ECT followed by maintenance ECT (mECT group) and those who did not (acute ECT [aECT] group) were included. Clinical characteristics, including the results of neuroimaging examinations for Parkinson\u2019s disease (PD) and dementia with Levy body (DLB) such as myocardial 123I-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter imaging single-photon emission computerized tomography (DaT-SPECT), were compared between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 13 and 146 patients were included in the mECT and aECT groups, respectively. Compared to the aECT group, the mECT group showed a significantly higher prevalence of melancholic features (92.3% vs. 27.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and catatonic features (46.2% vs. 9.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Overall, 8 of the 13 patients in the mECT group and 22 of the 146 patients in the aECT group underwent neuroimaging examinations for PD\/DLB. The rate of patients examined is significantly higher in the mECT group than in the aECT group (61.5% vs. 11.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Among the groups examined, 7\/8 patients in the mECT group and 16\/22 patients in the aECT group showed relevant neuroimaging findings for PD\/DLB; the positive rate was not significantly different between the two groups (87.5% vs. 72.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.638).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients who receive acute and maintenance ECT may have underlying neurodegenerative diseases, including PD\/DLB. Investigating the neurobiology of patients who receive maintenance ECT is important for developing appropriate treatments for depression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-023-04743-7","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T13:02:53Z","timestamp":1681218173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical characteristics and potential association to Parkinson\u2019s disease and dementia with Lewy bodies in patients with major depressive disorder who received maintenance electroconvulsive therapy: a retrospective chart review study"],"prefix":"10.1186","volume":"23","author":[{"given":"Shun","family":"Kudo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Takamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bun","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinichi","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"4743_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1177\/0004867419839139","volume":"53","author":"A Weiss","year":"2019","unstructured":"Weiss A, Hussain S, Ng B, Sarma S, Tiller J, Waite S, et al. Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of electroconvulsive therapy. Aust N Z J Psychiatry. 2019;53:609\u201323.","journal-title":"Aust N Z J Psychiatry"},{"key":"4743_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2215-0366(15)00505-2","volume":"3","author":"D Vigo","year":"2016","unstructured":"Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry. 2016;3:171\u20138.","journal-title":"Lancet Psychiatry"},{"key":"4743_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/acps.13335","volume":"144","author":"P Cuijpers","year":"2021","unstructured":"Cuijpers P, Karyotaki E, Ciharova M, Miguel C, Noma H, Furukawa TA. The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta-analysis. Acta Psychiatr Scand. 2021;144:288\u201399.","journal-title":"Acta Psychiatr Scand"},{"key":"4743_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1056\/NEJM200005183422001","volume":"342","author":"MB Keller","year":"2000","unstructured":"Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000;342:282\u201390.","journal-title":"N Engl J Med"},{"key":"4743_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/archpsyc.1984.01790120037006","volume":"41","author":"GE Murphy","year":"1984","unstructured":"Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Cognitive therapy and pharmacotherapy. Singly and together in the treatment of depression. Arch Gen Psychiatry. 1984;41:33\u201341.","journal-title":"Arch Gen Psychiatry."},{"key":"4743_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12877-019-1327-4","volume":"19","author":"L Mallery","year":"2019","unstructured":"Mallery L, MacLeod T, Allen M, McLean-Veysey P, Rodney-Cail N, Bezanson E, et al. Systematic review and meta-analysis of second-generation antidepressants for the treatment of older adults with depression: questionable benefit and considerations for frailty. BMC Geriatr. 2019;19:306.","journal-title":"BMC Geriatr"},{"key":"4743_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1399-5618.2012.00997.x","volume":"14","author":"B Dierckx","year":"2012","unstructured":"Dierckx B, Heijnen WT, van den Broek WW, Birkenh\u00e4ger TK. Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a meta-analysis. Bipolar Disord. 2012;14:146\u201350.","journal-title":"Bipolar Disord"},{"key":"4743_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S0140-6736(03)12705-5","volume":"361","author":"J Geddes","year":"2003","unstructured":"Geddes J, Carney S, Cowen P, Goodwin G, Rogers R, Dearness K, et al. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361:799\u2013808.","journal-title":"Lancet"},{"key":"4743_CR9","first-page":"23","volume":"17\u201318","author":"Z Yao","year":"2019","unstructured":"Yao Z, McCall WV, Essali N, Wohl E, Parker C, Rosenquist PB, et al. Precision ECT for major depressive disorder: A review of clinical factors, laboratory, and physiologic biomarkers as predictors of response and remission. Pers Med Psychiatry. 2019;17\u201318:23\u201331.","journal-title":"Pers Med Psychiatry"},{"key":"4743_CR10","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1038\/npp.2013.149","volume":"38","author":"A Jelovac","year":"2013","unstructured":"Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: A meta-analysis. Neuropsychopharmacology. 2013;38:2467\u201374.","journal-title":"Neuropsychopharmacology"},{"key":"4743_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4088\/JCP.08m04092","volume":"70","author":"KG Rasmussen","year":"2009","unstructured":"Rasmussen KG, Mueller M, Rummans TA, Husain MM, Petrides G, Knapp RG, et al. Is baseline medication resistance associated with potential for relapse after successful remission of a depressive episode with ECT? Data from the Consortium for Research on Electroconvulsive Therapy (CORE). J Clin Psychiatry. 2009;70:232\u20137.","journal-title":"J Clin Psychiatry"},{"key":"4743_CR12","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/jama.285.10.1299","volume":"285","author":"HA Sackeim","year":"2001","unstructured":"Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: A randomized controlled trial. J Am Med Assoc. 2001;285:1299\u2013307.","journal-title":"J Am Med Assoc"},{"key":"4743_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/0004867417743343","volume":"52","author":"A Elias","year":"2018","unstructured":"Elias A, Phutane VH, Clarke S, Prudic J. Electroconvulsive therapy in the continuation and maintenance treatment of depression: Systematic review and meta-analyses. Aust N Z J Psychiatry. 2018;52:415\u201324.","journal-title":"Aust N Z J Psychiatry"},{"key":"4743_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jad.2013.11.005","volume":"156","author":"A Elias","year":"2014","unstructured":"Elias A, Chathanchirayil SJ, Bhat R, Prudic J. Maintenance electroconvulsive therapy up to 12 years. J Affect Disord. 2014;156:228\u201331.","journal-title":"J Affect Disord"},{"key":"4743_CR15","volume-title":"The practice of electroconvulsive therapy\u202f: recommendations for treatment, training, and privileging\u202f: a task force report of the American Psychiatric Association","author":"American Psychiatric Association","year":"2001","unstructured":"American Psychiatric Association. The practice of electroconvulsive therapy\u202f: recommendations for treatment, training, and privileging\u202f: a task force report of the American Psychiatric Association. 2001."},{"key":"4743_CR16","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195148206.001.0001","volume-title":"Electroconvulsive therapy","author":"R Abrams","year":"2002","unstructured":"Abrams R. Electroconvulsive therapy. 2002."},{"key":"4743_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/YCT.0000000000000484","volume":"35","author":"SP Gill","year":"2019","unstructured":"Gill SP, Kellner CH. Clinical Practice Recommendations for Continuation and Maintenance Electroconvulsive Therapy for Depression: Outcomes from a Review of the Evidence and a Consensus Workshop Held in Australia in May 2017. J ECT. 2019;35:14\u201320.","journal-title":"J ECT"},{"key":"4743_CR18","volume-title":"Practice Guideline For The Treatment of Patients With Major Depressive Disorder 3rd edition","author":"American Psychiatric Association","year":"2010","unstructured":"American Psychiatric Association. Practice Guideline For The Treatment of Patients With Major Depressive Disorder 3rd edition. 2010."},{"key":"4743_CR19","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1212\/WNL.0000000000001684","volume":"84","author":"H Gustafsson","year":"2015","unstructured":"Gustafsson H, Nordstr\u00f6m A, Nordstr\u00f6m P. Depression and subsequent risk of Parkinson disease A nationwide cohort study. Neurology. 2015;84:2422\u20139.","journal-title":"Neurology"},{"key":"4743_CR20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/pcn.13485","volume":"76","author":"I Kawakami","year":"2022","unstructured":"Kawakami I, Iga J ichi, Takahashi S, Lin YT, Fujishiro H. Towards an understanding of the pathological basis of senile depression and incident dementia: Implications for treatment. Psychiatry Clin Neurosci. 2022;76:620\u201332.","journal-title":"Psychiatry Clin Neurosci."},{"key":"4743_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1479-8301.2009.00292.x","volume":"9","author":"S Takahashi","year":"2009","unstructured":"Takahashi S, Mizukami K, Yasuno F, Asada T. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics. 2009;9:56\u201361.","journal-title":"Psychogeriatrics"},{"key":"4743_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.12998\/wjcc.v3.i8.682","volume":"3","author":"M Baquero","year":"2015","unstructured":"Baquero M. Depressive symptoms in neurodegenerative diseases. World J Clin Cases. 2015;3:682.","journal-title":"World J Clin Cases"},{"key":"4743_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/0269881113478282","volume":"27","author":"FL Rocha","year":"2013","unstructured":"Rocha FL, Murad MGR, Stumpf BP, Hara C, Fuzikawa C. Antidepressants for depression in Parkinson\u2019s disease: Systematic review and meta-analysis. J Psychopharmacol. 2013;27:417\u201323.","journal-title":"J Psychopharmacol"},{"key":"4743_CR24","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5)","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5). 2013."},{"key":"4743_CR25","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and Statistical Manual of Mental Disorders 4th edition, Text Revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th edition, Text Revision (DSM-IV-TR). 2000."},{"key":"4743_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/YIC.0b013e328303ac75","volume":"23","author":"M Nos\u00e8","year":"2008","unstructured":"Nos\u00e8 M, Tansella M, Thornicroft G, Schene A, Becker T, Veronese A, et al. Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages? Int Clin Psychopharmacol. 2008;23:287\u201390.","journal-title":"Int Clin Psychopharmacol"},{"key":"4743_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, DIckson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology."},{"key":"4743_CR28","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601.","journal-title":"Mov Disord"},{"key":"4743_CR29","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/jnnp-2017-317398","volume":"89","author":"J Komatsu","year":"2018","unstructured":"Komatsu J, Samuraki M, Nakajima K, Arai H, Arai H, Arai T, et al. 123I-MIBG myocardial scintigraphy for the diagnosis of DLB: a multicentre 3-year follow-up study. J Neurol Neurosurg Psychiatry. 2018;89:1167\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4743_CR30","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00259-006-0155-x","volume":"33","author":"L Tossici-Bolt","year":"2006","unstructured":"Tossici-Bolt L, Hoffmann SMA, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: An accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006;33:1491\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4743_CR31","volume-title":"ECDEU assessment manual for psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. 1976."},{"key":"4743_CR32","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.brs.2017.10.009","volume":"11","author":"TS Kaster","year":"2018","unstructured":"Kaster TS, Goldbloom DS, Daskalakis ZJ, Mulsant BH, Blumberger DM. Electroconvulsive therapy for depression with comorbid borderline personality disorder or post-traumatic stress disorder: A matched retrospective cohort study. Brain Stimul. 2018;11:204\u201312.","journal-title":"Brain Stimul"},{"key":"4743_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/da.22774","volume":"35","author":"MS Cepeda","year":"2018","unstructured":"Cepeda MS, Reps J, Ryan P. Finding factors that predict treatment-resistant depression: Results of a cohort study. Depress Anxiety. 2018;35:668\u201373.","journal-title":"Depress Anxiety"},{"key":"4743_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.psychres.2016.04.034","volume":"240","author":"V De Carlo","year":"2016","unstructured":"De Carlo V, Calati R, Serretti A. Socio-demographic and clinical predictors of non-response\/non-remission in treatment resistant depressed patients: A systematic review. Psychiatry Res. 2016;240:421\u201330.","journal-title":"Psychiatry Res"},{"key":"4743_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/fampra\/cmq076","volume":"28","author":"K Suija","year":"2011","unstructured":"Suija K, Aluoja A, Kalda R, Maaroos HI. Factors associated with recurrent depression: A prospective study in family practice. Fam Pract. 2011;28:22\u20138.","journal-title":"Fam Pract"},{"issue":"102","key":"4743_CR36","first-page":"56","volume":"2019","author":"CPC Galts","year":"2018","unstructured":"Galts CPC, Bettio LEB, Jewett DC, Yang CC, Brocardo PS, Rodrigues ALS, et al. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neurosci Biobehav Rev. 2018;2019(102):56\u201384.","journal-title":"Neurosci Biobehav Rev"},{"key":"4743_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/mds.28335","volume":"36","author":"A Takamiya","year":"2021","unstructured":"Takamiya A, Seki M, Kudo S, Yoshizaki T, Nakahara J, Mimura M, et al. Electroconvulsive Therapy for Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis. Mov Disord. 2021;36:50\u20138.","journal-title":"Mov Disord"},{"key":"4743_CR38","first-page":"193","volume":"32","author":"EM Strome","year":"2007","unstructured":"Strome EM, Zis AP, Doudet DJ. Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats. J Psychiatry Neurosci. 2007;32:193.","journal-title":"J Psychiatry Neurosci"},{"key":"4743_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000334497","volume":"9","author":"AM Landau","year":"2012","unstructured":"Landau AM, Clark C, Jivan S, Doudet DJ. Antiparkinsonian mechanism of electroconvulsive therapy in MPTP-lesioned non-human primates. Neurodegener Dis. 2012;9:128\u201338.","journal-title":"Neurodegener Dis"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-023-04743-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T09:45:34Z","timestamp":1702201534000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-023-04743-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4743"],"URL":"https:\/\/doi.org\/10.1186\/s12888-023-04743-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2102779\/v1","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]},"assertion":[{"value":"26 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Keio University School of Medicine, Tokyo, Japan. The waiver for consent to participate is provided by the ethics committee of Keio University School of Medicine, Tokyo, Japan. We further confirm that all methods were employed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TU has received grants from SENSHIN Medical Research Foundation (Osaka, Japan) within the past two years. BY has received grants from Brain Energy Inc (Tokyo, Japan) within the past two years. MM has received speaker\u2019s honoraria from Biogen Japan, Byer Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Demant Japan, Eisai, Eli Lilly, Fuji Film RI Pharma, Hisamitsu Pharmaceutical, H.U. Frontier, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Mylan EPD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Yakuhin, Teijin Pharma, and Viatris within the past two years. Also, he received grants from Daiichi Sankyo, Eisai, Fronteo, Shionogi, Takeda, Tanabe Mitsubishi and Tsumura within the past two years outside the submitted work. JH has received speaker\u2019s honoraria from Dainippon-Sumitomo Pharma within the past two years.\u00a0All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}